#United States #New York #Pomerantz Law #argenx SE #Vyvgart Hytrulo

Overview

Pomerantz LLP, a leading law firm, has initiated an investigation regarding potential claims involving argenx SE (NASDAQ: ARGX) on behalf of its investors. The probe comes in light of alarming allegations suggesting that argenx and some of its executives may have engaged in securities fraud or other illicit business practices.

Current Situation

On June 30, 2025, the U.S. Food and Drug Administration (FDA) issued a public warning concerning argenx’s drug, Vyvgart Hytrulo. The warning highlights a potential serious risk associated with the medication, specifically a possible exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy. This is based on reports documented in the FDA Adverse Event Reporting System. Consequently, the FDA indicated that it is assessing the need for regulatory actions related to this issue.

Following the FDA's notification, the price of argenx’s American Depositary Shares (ADS) witnessed a significant drop, declining by $8.92 per share, or 1.59%, closing at $551.22 per ADS on the same day. Such price movements could indicate investor anxiety and a potential loss of confidence in the company’s operations and product safety.

Legal Action

As a result of these developments, Pomerantz LLP is reaching out to investors who may have been affected by these events. The firm encourages anyone holding investments in argenx to contact attorney Danielle Peyton for more information on joining the ongoing class action. This investigation seeks to ensure that any investors negatively impacted by possible securities violations receive justice and appropriate compensation.

About Pomerantz LLP

Established by the late Abraham L. Pomerantz, known as the pioneer in securities class action litigation, Pomerantz LLP boasts a distinguished legacy of advocating for investors’ rights. The firm has its headquarters in New York and maintains offices in Chicago, Los Angeles, London, Paris, and Tel Aviv. Their track record includes recovering numerous multimillion-dollar awards for clients affected by corporate misconduct. Pomerantz's commitment to holding companies accountable for their actions remains strong, as they continue to navigate the complexities of securities law in pursuit of justice for investors.

Investors who may have questions or seek further insights into this evolving situation are urged to reach out to the firm. Pomerantz remains diligent in its mission to uncover the truth and stand up against corporate wrongdoing. For any additional information on how to proceed with claims or to learn about the ongoing investigation, please contact Danielle Peyton at the provided email or phone number.

Conclusion

The situation with argenx SE reflects broader industry challenges where drug safety and corporate accountability are of utmost importance. As this investigation unfolds, it remains imperative for investors to stay informed and consider their positions in relation to the ongoing developments around argenx and its product offerings.